Portal de investigación
A multicenter open-label extension study to evaluate the long-term safety and tolerability of zigakibart in adults with primary IgA nephropathy.
Datos básicos
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
NOVARTIS PHARMA AG
Cita
A multicenter open-label extension study to evaluate the long-term safety and tolerability of zigakibart in adults with primary IgA nephropathy. (CFUB523A12302B). NOVARTIS PHARMA AG. 2026IP:RAFAEL GARCÍA MASET.